Mechanism of action of the trastuzumab biosimilar CT-P6. (3rd October 2019)

• Record Type: Journal Article
• Authors: Jeong, Sun Ah; Choi, Jung Min; Park, Jun Mo; Lee, Jun Young; Lee, So Jung; Lee, Su Yeon; Lee, Si Yeon; Park, Yoon A; Jeong, Hee Jeong; Song, Yoo Cheol; Kim, Sung Hwan; Chang, Shin Jae
• Is Part Of: Expert opinion on biological therapy. Volume 19:Number 10(2019)
• Page Start: 1085
• Page End: 1095
• Publication Date: 2019-10-03
• Subjects: Biosimilar -- breast cancer -- CT-P6 -- gastric cancer -- mechanism of action -- trastuzumab; Gene therapy -- Periodicals; Protein drugs -- Periodicals; Peptide drugs -- Periodicals; Immunotherapy -- Periodicals; Drug delivery systems -- Periodicals; 615.5
• DOI: 10.1080/14712598.2019.1554052
• Languages: English
• ISSNs: 1471-2598

Abstract

ABSTRACT: Objectives : Therapeutic monoclonal antibody biosimilars are expected to help reduce the sizeable economic burden of targeted treatments. Trastuzumab (Herceptin®), a recombinant humanized monoclonal antibody that binds to the extracellular domain of HER2, is approved for use in HER2-overexpressing breast cancer (in both the adjuvant and metastatic settings) and HER2-positive gastric cancer. CT-P6 (Herzuma®) is a biosimilar of trastuzumab, designed to bind with high affinity and specificity to the same HER2 epitope as the reference product. We investigated whether CT-P6 exerts its effects through the same mechanism of action as trastuzumab. Methods : The mechanism of action of CT-P6 and trastuzumab, both as monotherapy and in combination with paclitaxel or pertuzumab, was compared in HER2-overexpressing breast cancer and gastric cancer cell models. Results : We confirmed that CT-P6 functions in a manner similar to trastuzumab by binding to the HER2 receptor, which is central to the effects of trastuzumab in all indications. Conclusions : Collectively, the results of this study show that the mechanisms of action of CT-P6 and trastuzumab are similar in HER2-positive breast cancer and gastric cancer models and, therefore, CT-P6 can be expected to perform similarly in the clinical setting.